Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q3 2012 · 10-Q
Revenue$238.00K$238.00K−36.0% vs Q3 2011 Net Income-$31.66M-$31.66MN/M vs Q3 2011 EPS Diluted-$0.06-$0.06N/M vs Q3 2011 Operating Income-$31,216,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$24,203,000N/M Margins · derivedOperating margin-13116.0%−5304.1 pt vs Q3 2011
Net margin-13301.7%−5361.1 pt vs Q3 2011
ended Sep 30, 2013 · filed Nov 12, 2013 · 43 d after period end